Buscar
Ascendis Pharma A/S
ASNDAñadir a la lista de seguimiento
261.580USD
+23.570+9.90%
Cierre 06/25, 16:00（ET）Cotizaciones retrasadas 15 min
16.21BCap. mercado
37.69P/E TTM
Más Datos de Ascendis Pharma A/S Compañía
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Información de Ascendis Pharma A/S
Símbolo de cotizaciónASND
Nombre de la empresaAscendis Pharma A/S
Fecha de salida a bolsaJan 28, 2015
Director ejecutivoMoller Mikkelsen (Jan)
Número de empleados- -
Tipo de seguridadDepository Receipt
Fin del año fiscalJan 28
DirecciónTuborg Boulevard 12
CiudadHELLERUP
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísDenmark
Código postal2900
Teléfono4570222244
Sitio Webhttps://ascendispharma.dk/
Símbolo de cotizaciónASND
Fecha de salida a bolsaJan 28, 2015
Director ejecutivoMoller Mikkelsen (Jan)
Ejecutivos de Ascendis Pharma A/S
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
Dr. Stina Singel, M.D., Ph.D.
Dr. Stina Singel, M.D., Ph.D.
Executive Vice President, Head of Clinical Development, Oncology
Executive Vice President, Head of Clinical Development, Oncology
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
--
-100.00%
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
11.39K
--
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+66.49%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
2.66K
+40.20%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.16K
+49.63%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
1.10K
+66.82%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
--
-100.00%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ascendis Pharma A/S?
Los cinco principales accionistas de Ascendis Pharma A/S son: Mr. Flemming Steen Jensen
¿Cuántas instituciones poseen acciones de Ascendis Pharma A/S (ASND)?
A fecha de 2026Q1, 582 instituciones poseen acciones de Ascendis Pharma A/S, con un valor de mercado combinado de aproximadamente 69.20M, lo que representa el 111.42% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1676383.00.
¿Cuál es la mayor fuente de ganancias de Ascendis Pharma A/S?
El 2026Q1, el segmento empresarial Commercial sale of products generó la ganancia más alta para Ascendis Pharma A/S, ascendiendo a 683.57M y representando el 94.92% de la ganancia total.
